ArticleThe oncologist2019
Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study.
Article in The oncologist, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Tumour profiling tests to guide adjuvant chemotherapy decisions in lymph node-positive early breast cancer: a systematic review and economic evaluation.Health technology assessment (Winchester, England) · 2025Pooled it
- Gene expression profiling tests to guide adjuvant chemotherapy decisions in lymph node-positive early breast cancer: a systematic review.Breast cancer research and treatment · 2025Pooled it
- Budget impact analysis of Oncotype DXThe European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Adjuvant S-1 plus endocrine therapy for ER-positive, HER2-negative, primary breast cancer: post-POTENT trial prognostic survey.NPJ breast cancer · 2025Article
- Nomogram construction and survival analysis in T3N0M0 breast cancer: a SEER population-based analysis.Scientific reports · 2025Article
- Characteristics of premenopausal breast cancer patients with a midrange 21-gene recurrence score.Annals of surgical treatment and research · 2025Article
- Prognosis, treatment decision-making and value: A qualitative exploration of the emerging role of breast cancer prognostic assays.PloS one · 2025Article
- Irish national real-world analysis of the clinical and economic impact of 21-gene oncotype DX® testing in early-stage, 1-3 lymph node-positive, oestrogen receptor-positive, HER2-negative, breast cancer.Breast cancer research and treatment · 2025Observational
- How to Tackle Discordance in Adjuvant Chemotherapy Recommendations by Using Oncotype DX Results, in Early-Stage Breast Cancer.Cancers · 2024Article
- Gene Expression Assays to Tailor Adjuvant Endocrine Therapy for HR+/HER2- Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Review
- Decision Impact Analysis to Measure the Influence of Molecular Signature Response Classifier Testing on Treatment Selection in Rheumatoid Arthritis.Rheumatology and therapy · 2024Article
- The utility of the 21-gene Oncotype DX Breast Recurrence ScoreContemporary oncology (Poznan, Poland) · 2024Article
- Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer.NPJ breast cancer · 2023Article
- Decision impact studies, evidence of clinical utility for genomic assays in cancer: A scoping review.PloS one · 2023Article
- Precision Medicine in Breast Cancer: Do MRI Biomarkers Identify Patients Who Truly Benefit from the Oncotype DX Recurrence ScoreDiagnostics (Basel, Switzerland) · 2022Article
- Impact of the 21-Gene Recurrence Score Assay on Treatment Decisions and Cost in Patients with Node-Positive Breast Cancer: A Multicenter Study in Quebec.The oncologist · 2022Observational
- Article
- Addressing the problem of overtreatment in breast cancer.Expert review of anticancer therapy · 2022Review
- The Role of the 21-Gene Recurrence ScoreCurrent oncology (Toronto, Ont.) · 2022Review
- Impact of the EndoPredict genomic assay on treatment decisions for oestrogen receptor-positive early breast cancer patients: benefits of physician selective testing.Breast cancer research and treatment · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 9 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe ROXANE Italian prospective study evaluated the impact of the 21-gene Recurrence Score (RS) results on adjuvant treatment decision for patients with early breast cancer. MATERIALS AND
methodsNine centers participated. Physicians used the RS test whenever unsure about adjuvant treatment recommendation for patients with estrogen receptor-positive/human epidermal growth receptor 2-negative, T1-T3, N0-N1 early breast cancer. Pre-RS and post-RS treatment recommendations were collected.
resultsA total of 251 patients were included. N0 patients (61%) showed higher grade (
conclusionPhysicians predominantly used the 21-gene assay in N0 patients with a more aggressive biology or in N1 patients showing more indolent biology. In this selected patient population, the use of RS testing led to a 30% rate of change in treatment decision. In the N1 patient subgroup, the use of RS testing contributed to reduce CT use by more than half. IMPLICATIONS FOR PRACTICE: This study shows that, even in a context in which physicians recommend a high proportion of patients to endocrine treatment alone before knowing the results of the Recurrence Score (RS) assay, the use of the RS test, whenever uncertainty regarding adjuvant treatment recommendation is present, significantly contributes in further reducing the use of chemotherapy, especially for N1 patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.